FDA approves Cablivi for treatment of adult acquired thrombosis platelet-reducing cyanosis

aTTP is a rare life-threatening disease that causes blood clotting, and Cablivi is the firstdrug to combine plasma exchange with immunosuppressive therapy to use the disease
http://recently,FDA(http://approved Cablivi (Caplacizumab-Yhdp) for the treatment of adult acquired thrombosis platelet-reducing cyanosis (aTTP)About CabliviCablivi is the first specific aTTP treatment drug and the first nanoantibody drug to be approved for marketCablivi is the first targeted treatment to inhibit the formation of blood clots, providing new treatment options for reducing recurrence in patients with aTTPCablivi's effectiveness was based on a clinicaltrial(http://in a clinicaltrial in which they were randomly treated with Cablivi or placeboThe two groups received plasma replacement and immunosuppressive therapy, respectivelyresults showed that patients treated with Cablivi had a faster improvement in platelet counts than placebos, and that the total number of aTTP-related deaths and recurrences decreased during treatment 　　Throughout the study period (the drug treatment period plus the 28-day follow-up period after discontinuation), the relapse rate was 38% in the placebo group, compared with 13% in the Cablivi group 　　In terms of safety
clinical trials, patients report that Cablivi's common side effects are nosebleeds or gum bleeding, as well as headaches Medical friends in Handing remind doctors and patients to be alert to the risk of severe bleeding when using Cablivi